Hydnocarpus Pentandra Nanosuspension And In Vitro Anti Cancer Studies Against MCF7 Cell Line

Hydnocarpus pentandra, a medicinal plant widely known for its bioactive compounds, has shown significant therapeutic potential in various disease treatments. In recent years, nanotechnology-based drug delivery systems have gained attention for enhancing the efficacy of plant-derived bioactive compounds. This study focuses on the formulation and evaluation of Hydnocarpus pentandra nanosuspension and its in vitro anticancer activity against the MCF-7 breast cancer cell line. The nanosuspension was prepared using an optimized nano-precipitation technique, ensuring high drug loading efficiency, stability, and enhanced bioavailability. Characterization of the nanosuspension was carried out through particle size analysis, zeta potential measurement, polydispersity index (PDI), and scanning electron microscopy (SEM) to determine its morphology, stability, and dispersibility. The anticancer potential of the Hydnocarpus pentandra nanosuspension was evaluated through MTT assay, which measures cell viability in response to different concentrations of the formulation. The results demonstrated a dose-dependent cytotoxic effect on MCF-7 cells, indicating significant anticancer activity. The nanosuspension exhibited improved cellular uptake and enhanced cytotoxicity compared to the crude extract, suggesting that the nanoformulation plays a crucial role in increasing the bioavailability of the active compounds. Additionally, fluorescence microscopy and flow cytometry studies were performed to analyze apoptosis induction and cell cycle arrest mechanisms. The findings suggest that Hydnocarpus pentandra nanosuspension effectively inhibits the proliferation of MCF-7 cells through apoptosis-mediated pathways. The enhanced solubility, targeted drug delivery, and improved therapeutic efficacy of the nanosuspension make it a promising candidate for breast cancer treatment. Furthermore, the study highlights the potential of nanotechnology-based phytomedicines in cancer therapy, providing a novel approach for drug development. Future research should focus on in vivo studies and mechanistic evaluations to establish the clinical applicability of Hydnocarpus pentandra nanosuspension in oncology.